Korean pharmaceutical induction seal bond strength for oral liquid containers is typically specified by the Korean pharmaceutical brand’s QA team in terms of peel force (N/15mm width) or container hermetic integrity (pass/fail bubble test at specified pressure). Standard Korean oral liquid induction seal specifications: peel force ≥ 8 N/15mm after 30-second induction sealing at the specified sealer power; bubble test hermetic pass at 10 kPa positive pressure for a minimum of 30 seconds (per ASTM F2096). IBM achieves these specifications through three simultaneous mechanism contributions: (1) Surface quality — IBM sealing land Ra ≤ 0.05 μm provides maximum foil-to-HDPE contact area per unit of sealing pressure, compared to EBM’s Ra 0.25–0.80 μm which leaves gaps between foil and sealing surface that become leak paths at low bubble test pressure; (2) Flatness — IBM sealing land flatness ±0.10 mm TIR ensures the induction sealer’s electromagnetic field heats the foil uniformly around the full perimeter of the sealing land, producing uniform bond strength at all angular positions around the neck circumference; (3) Dimensional consistency — IBM neck OD ±0.05 mm ensures the induction sealer’s head contacts the foil evenly across all production containers, producing consistent sealer dwell contact time at all cavities’ sealing lands. Korean pharmaceutical brands specify the induction seal foil type, sealer power and dwell time as part of their Korean KFDA container technical file — these parameters must be validated against IBM containers produced at the commercial production conditions, not against laboratory-scale trial containers.

IBM achieves Korean KFDA ±5% fill-volume tolerance through the combination of two IBM-specific advantages: preform-defined body volume and blow mould-defined graduation mark position. In IBM, the preform’s geometry — controlled by the injection mould — determines the distribution of HDPE polymer in the finished container. The IBM blow mould then defines the final body shape, including the diameter at each axial position. Because both the preform geometry and the blow mould dimensions are machined to ±0.02 mm dimensional tolerance, the container body volume at the graduation mark position is repeatable to approximately ±2–3% across all cavities and production cycles — well within the ±5% Korean KFDA fill tolerance. The graduation mark position on the IBM blow mould cavity wall is calibrated during Korea Ever-Power’s pre-delivery production trial by filling 100 sample containers with water at 23°C and measuring the fill volume at the mark position. If any cavity’s mark position produces a fill volume error exceeding ±3% (below ±5% Korean KFDA limit but exceeding Korea Ever-Power’s tighter pre-delivery target), the blow mould cavity groove is re-machined at the corrected axial position before final delivery. EBM containers achieve ±5% volume tolerance less consistently because EBM wall thickness variation (±15% CV% versus IBM’s ±3–6% CV%) produces inter-cavity and inter-cycle body diameter variation that shifts the actual fill volume at the graduation mark position unpredictably — some EBM cavities produce containers where the graduation mark is at a fill position up to ±8–12% from nominal due to wall thickness and body diameter variation, exceeding the Korean KFDA fill tolerance.

Yes, amber HDPE oral liquid IBM containers are produced using iron oxide-based amber masterbatch at 0.3–0.8% loading in HDPE — iron oxide is on the Korean KFDA pharmaceutical positive list as an approved colourant for pharmaceutical packaging materials. Korean light-sensitive oral pharmaceutical formulations that specify amber IBM containers include riboflavin (Vitamin B2) liquid preparations, certain Korean oral antibiotic formulations with light-sensitive active ingredients, and Korean oral iron supplement liquids where iron ion stability requires UV barrier packaging. The amber masterbatch addition requires additional Korean KFDA pharmaceutical container qualification steps versus natural HDPE oral liquid containers: new Korean KP extractables testing of the amber HDPE grade (the masterbatch carrier resin adds extractable potential that must be tested separately from the base HDPE resin); ICH Q1B photostability data for the specific Korean pharmaceutical formulation in amber IBM container (confirming the amber HDPE provides sufficient UV barrier at the IBM body wall thickness to protect the active ingredient throughout the 24-month Korean shelf life at Korean retail storage conditions). Korea Ever-Power sources amber pharmaceutical IBM masterbatch from Korean and international masterbatch suppliers who maintain Korean KFDA pharmaceutical contact declarations for their iron oxide masterbatch formulations, and can provide masterbatch supplier declarations as part of the pharmaceutical container technical file documentation package.

No — each IBM mould set is dimensionally specific to a single container volume, height and body diameter. The IBM injection mould defines the preform geometry, the blow mould defines the finished container body shape including volume and graduation mark position, and the stripping tool is dimensioned for the specific container height. A 60 ml oral liquid mould set cannot produce 100 ml containers because: the blow mould cavity volume is 60 ml, not 100 ml (inflation of a 60 ml preform against a 100 ml blow mould would produce a container with uncontrolled thin spots at the body shoulder where preform material is insufficient to cover the larger body surface area); the graduation mark position is calibrated for 60 ml fill volume, not 100 ml; and the preform shot weight is designed for 60 ml body volume. Korean pharmaceutical IBM producers who produce both 60 ml and 100 ml oral liquid containers on the same ZQ machine must maintain two separate mould sets — one for each volume. Korea Ever-Power recommends ordering both mould sets simultaneously at machine purchase to control delivery timelines and ensure volume mark calibration across both formats is completed within the same pre-delivery qualification window. The Korean KFDA pharmaceutical container technical file (CTF) must include separate documentation for each volume/mould set combination — the 60 ml CTF and 100 ml CTF are independent regulatory documents even when both are produced on the same qualified ZQ machine.